Registry for patients with Immune Thrombocytopenia and biospecimen collection

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This registry aims to collect clinical information and biospecimens from patients diagnosed with Immune Thrombocytopenia (ITP) at various stages of their disease. By gathering real-world data, the registry seeks to enhance understanding of ITP diagnosis and treatment, ultimately guiding patients to more effective therapies. The study will collect a wide range of clinical measures, treatment outcomes, and quality of life data over a period of up to five years. Patients can be included both prospectively and retrospectively, provided they meet the eligibility criteria and have continuous documentation.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Primary or secondary Immune Thrombocytopenia (ITP)
* Age ≥18 years
* signed declaration of consent

Exclusion Criteria:

* diagnoses that cannot be reconciled with the diagnosis of ITP (esp. heparin-induced thrombocytopenia, pregnancy-associated thrombocytopenia, pseudothrombocytopenia)
* no informed consent possible (this covers patients who are unable to understand the nature and scope of participation)

Where it's running

• Universitätsklinikum Aachen AöR
  Aachen, Germany Recruiting
• Klinikum Altenburger Land GmbH, Klinik für Innere Medizin/Hämatologie/Onkologie
  Altenburg, Germany Recruiting
• MVZ am Klinikum Aschaffenburg
  Aschaffenburg, Germany Recruiting
• MVZ IMD GmbH, IMD Gerinnungszentrum Hochtaunus
  Bad Homburg, Germany Recruiting
• Onkologie/Hämatologie
  Bad Liebenwerda, Germany Recruiting
• Charité Universitätsmedizin Berlin
  Berlin, Germany Recruiting

+14 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: Thomas Stauch, Dr. med.
• Email: thomas.stauch@med.uni-jena.de
• Phone: 0049-3641-9326864

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Sirolimus added to standard therapy for adults with SLE-associated immune thrombocytopenia

  This trial tests whether adding sirolimus to usual treatment helps adults with SLE-related immune thrombocytopenia see their platelet counts improve.

  Recruiting Phase 2/3 Chinese SLE Treatment And Research Group · Beijing, Beijing Municipality · NCT07657793

• GL-2045 safety and blood-count help for adults with ITP

  GL-2045 is being tested in adults with immune thrombocytopenia to see if it can safely raise platelet counts like IVIg does.

  Recruiting Phase 1 Gliknik Inc. · Leeds · NCT07605845

• Eltrombopag use in adults with primary ITP: real-world patterns and outcomes

  This study looks at how eltrombopag is used in adult patients with primary ITP and what outcomes are seen in routine care.

  Recruiting Novartis · Basel · NCT07587723

• Daratumumab versus rituximab for children with primary immune thrombocytopenia

  This study will test whether daratumumab works better than rituximab to increase platelet counts in children aged 6–17 with primary ITP who did not respond to or relapsed after steroid treatment.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin · NCT07362238

• Daratumumab plus rituximab for adults with relapsed or refractory immune thrombocytopenia

  This treatment combines daratumumab (an anti‑CD38 antibody) with rituximab to see if it raises platelet counts in adults with ITP who haven't responded to steroids and other therapies.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07362199

• Daratumumab versus rituximab for adult primary immune thrombocytopenia

  This trial will test whether daratumumab (an anti‑CD38 antibody) works better than rituximab for adults with primary ITP who did not respond to or relapsed after steroid treatment.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07297563

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.